VSee Health, Inc. Financing Receivable Excluding Accrued Interest Credit Loss Expense Reversal
VSee Health, Inc. (VSEE) reported Financing Receivable Excluding Accrued Interest Credit Loss Expense Reversal of $872.12 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinancingReceivableExcludingAccruedInterestCreditLossExpenseReversal · last filed 2026-08-14
- VSee Health, Inc. financing receivable excluding accrued interest credit loss expense reversal for the quarter ending 2026-06-30 was $516.33K, a 309.90% increase year-over-year.
- VSee Health, Inc. financing receivable excluding accrued interest credit loss expense reversal for the quarter ending 2026-03-31 was $355.79K, a 194.24% increase year-over-year.
- VSee Health, Inc. financing receivable excluding accrued interest credit loss expense reversal for the quarter ending 2025-06-30 was $125.96K.
- VSee Health, Inc. financing receivable excluding accrued interest credit loss expense reversal for the quarter ending 2025-03-31 was $120.92K.
| Period end | Financing Receivable Excluding Accrued Interest Credit Loss Expense Reversal 3 month | Financing Receivable Excluding Accrued Interest Credit Loss Expense Reversal 6 month |
|---|---|---|
| 2026-06-30 | $516.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $872.12K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $355.79K 10-Q · filed 2026-05-15 | |
| 2025-06-30 | $125.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $246.88K 10-Q · filed 2026-08-14 |
| 2025-03-31 | $120.92K 10-Q · filed 2026-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Agape ATP Corp (ATPC) | $0.002B | ||
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |